Results of the Cox proportional hazard model
| β | HR | 95% CI | p Value | |
|---|---|---|---|---|
| Unadjusted model | ||||
| Etanercept | Reference | |||
| Adalimumab | 0.46 | 1.59 | 1.00 to 2.52 | 0.049 |
| Infliximab | 0.90 | 2.47 | 1.58 to 3.86 | 0.000 |
| Adjusted model | ||||
| Etanercept | Reference | |||
| Adalimumab | 0.61 | 1.83 | 1.49 to 2.26 | <0.001 |
| Infliximab | 0.71 | 2.04 | 1.62 to 2.58 | <0.001 |
| Age | 0.04 | 1.04 | 1.02 to 1.04 | <0.001 |
| DAS28, time-dependent | 0.19 | 1.21 | 1.13 to 1.29 | <0.001 |
| Year of starting anti-TNF therapy | −0.11 | 0.99 | 0.95 to 1.03 | 0.56 |
| Comorbidities | 0.55 | 1.73 | 1.40 to 2.13 | <0.001 |
Age, year of starting anti-TNF therapy and comorbidities acted as confounders and were measured at baseline.
DAS28, Disease Activity Score of 28 joints, measured over time (time-dependent); TNF, tumour necrosis factor.